This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by McGowan, E. Articles by Abbadie, C. PubMed PubMed Citation Articles by McGowan, E. Articles by Abbadie, C. Related Collections Mechanisms Pain Mechanisms Inflammation Preclinical Pharmacology Pain Pharmacology

---

ANALGESIA

A Peripherally Acting Na_v1.7 Sodium Channel Blocker Reverses Hyperalgesia and Allodynia on Rat Models of Inflammatory and Neuropathic Pain

From the Merck Research Laboratories, Department of Pharmacology and Medicinal Chemistry Rahway, New Jersey.

Address correspondence and reprint requests to Catherine Abbadie, PhD, Alcon Labs, 6201 South Freeway, Fort Worth, TX 76134-2099. Address e-mail to catherine.abbadie{at}alconlabs.com.

Abstract

BACKGROUND: Voltage-gated sodium channels (Na_v1) are expressed in primary sensory neurons where they influence excitability via their role in the generation and propagation of action potentials. Recently, human genetic data have shown that one sodium channel subtype, Na_v1.7, plays a major role in pain. We performed these studies to characterize the antinociceptive effects of N-[(R)-1-((R)-7-chloro-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-2-(2-fluorophenyl)-ethyl]-4-fluoro-2-trifluoromethyl-benzamide (BZP), a non-central nervous system (CNS) penetrant small molecule with high affinity and preferential selectivity for Na_v1.7 over Na_v1.8 and Na_v1.5.

METHODS: BZP was evaluated in rat preclinical models of inflammatory and neuropathic pain and compared with standard analgesics. Two models were used: the complete Freund’s adjuvant model of inflammatory pain and the spinal nerve ligation model of neuropathic pain. BZP was also evaluated in a motor coordination assay to assess its propensity for CNS side effects.

RESULTS: In preclinical models of chronic pain, BZP displayed efficacy comparable with that of leading analgesics. In the complete Freund’s adjuvant model, BZP produced reversal of hyperalgesia comparable with nonsteroidal antiinflammatory drugs, and in the spinal nerve ligation model, BZP produced reversal of allodynia comparable with gabapentin and mexiletine. Unlike the CNS penetrant compounds gabapentin and mexiletine, BZP did not induce any impairment of motor coordination.

CONCLUSIONS: These data suggest that a peripherally acting sodium channel blocker, preferentially acting through Na_v1.7, could provide clinical relief of chronic pain without the CNS side effects typical of many existing pain treatments.